The Government Observatory reported that Greece, while representing less than 5% of European pharmaceutical production in 2018 and being an importer, had developed a domestic pharmaceutical industry over the past seven years. According to the post, there were now 51 production units and 31 research and development centers operating in the country. The author noted that Greece exported pharmaceuticals to 147 countries and that these were the country's first exported industrial product, with a value of 2.75 billion euros. He added that investments exceeding 1.8 billion euros were underway, with Arcadia evolving into a pharmaceutical center. He cited examples such as Demo's investment in Tripoli amounting to 356 million euros, ELPEN's investment in Arcadia and Attica totaling 350 million euros, as well as investments by FARAN in Tripoli and Rontis in Larissa, totaling 180 million euros. According to the post, Greece was approaching 15% of European pharmaceutical production and would soon cover nearly 40% of European demand for penicillin-based medications and 35% for oncology drugs in Greece. The Government Observatory also claimed that the growth of the sector created jobs for thousands of Greek scientists and attributed this trajectory to the incentives of the investment clawback, which, it stated, was established by a government law. #ΦαρμακευτικήΒιομηχανία #Εξαγωγές #Ελλάδα (translated)
